The kind of fumbles Missling repeatedly makes are an invitation to lawsuits, frivolous or not. Low and behold, here we are. And the investors here warned of this possibility. Missling needs to be careful, or there will be more. Hopefully the AD paper will prove out odds risk in the SAP and head off another one.
Missling sometimes crosses the line between presenting results in a good light and inadvertently misleading. This is a public company and the TLRs are public statements for shareholders. You open yourself to not only private lawsuits but SEC actions. Tellingly, and thankfully, there has been no notice from the SEC. That can potentially change after legal discovery. (The SEC is usually not proactive enough to police trial releases, so private lawsuits are typically the catalyst for possible SEC actions in biotech.)
For those paying attention, the few investors here have pointed out flaws, grey areas, and open questions in our TLRs. We don't confirm desires, aren't"paid bashers", or any other dumb stuff; we're doing due diligence on our investment. Foolish speculators don't like it, but we don't do it for them. We do it for us.
News 
Market Data 
Discover 
